Financial Review: Rein Therapeutics (RNTX) & Its Rivals

Insider and Institutional Ownership

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 13.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Rein Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Rein Therapeutics’ peers have a beta of 4.19, indicating that their average share price is 319% more volatile than the S&P 500.

Profitability

This table compares Rein Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-74.08%	-27.93%
Rein Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Valuation & Earnings

This table compares Rein Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Rein Therapeutics	N/A	-$15.73 million	-0.66
Rein Therapeutics Competitors	$9.91 billion	$136.15 million	-5.40

Rein Therapeutics’ peers have higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Rein Therapeutics beats its peers on 5 of the 9 factors compared.

About Rein Therapeutics

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.